ATAI News and Press, ATAI Life Sciences N.V. From 11/10/22

Clinical-stage biopharmaceutical company atai Life Sciences (Nasdaq: ATAI) reported financial results for the third quarter ending Sept. 30, providing updates on its clinical trials looking at the treatment of depression using ketamine – particularly an at-home therapy for ...

ATAI Life Sciences press release ( NASDAQ: ATAI ): Q3 GAAP EPS of -$0.22 beats by $0.01 . In Q3, ATAI continued to advance its programs and is looking forward to additional clinical milestones for the remainder of 2022 and beyond. As of now, eight compounds are in ...

Last patient dosed in the Phase 2a proof-of-concept trial of PCN-101 (R-ketamine) for treatment-resistant depression (TRD), with topline results expected around year-end 2022. Announced positive preliminary pharmacokinetics and pharmacodynamics results in a Phase 1 study of GR...

ATAI Life Sciences ( NASDAQ: ATAI ) is scheduled to announce Q3 earnings results on Thursday, November 10th, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $0M. Over the last 3 months, EPS estimates have seen 2 upward r...

Edward J. Delaney, an American author who’s written fictional books such as “Follow the Sun” and “Warp and Weft,” recently published a new novel based on the life of Cary Grant. The novel in question, “ The Acrobat ,” focuses on Grant’...

The Women in Psychedelics Network (“ WIPN ” or “ Network ”), a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing opportunities to move mental health solutions forward, today announc...

atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company that specializes in the use of psychedelics to treat mental health conditions, saw its shares rise 14.58% on Tuesday. The stock closed at $2.95 on Monday then opened on Tuesday at $3.15. The stock ros...

Certain events bring about volatility that creates massive opportunities for traders on either side of the screen. That’s exactly what happened on Tuesday after a Berlin-based %Biotech company announced it plans to announce its third quarter 2022 financial results and business up...

For more than a year, a palliative care specialist has been fighting to be granted permission by the U.S. Drug Enforcement Administration (DEA) to administer psilocybin to his patients. Dr. Sunil Aggarwal had requested a federal waiver under the Right to Try statute , which would have all...

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthc...